ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      97,476.01
      -0.29%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Atea Pharmaceuticals Inc (AVIR) Quote

      Atea Pharmaceuticals Inc

      Atea Pharmaceuticals Inc (AVIR)

      NASDAQ
      3.19
      0.06
      (1.92%)
      Closed December 21 4:00PM
      Delayed by 15 minutes
      3.19
      -0.02
      (-0.62%)
      After Hours: 6:56PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      3.19
      Bid
      3.19
      Ask
      3.28
      Volume
      1,153,930
      3.15 Day's Range 3.315
      2.30 52 Week Range 4.60
      Market Cap
      269.437M
      Previous Close
      3.13
      Open
      3.155
      Last Trade
      3305
      @
      3.19
      (priorref)
      Last Trade Time
      Financial Volume
      $ 3,753,690
      VWAP
      3.253
      Average Volume (3m)
      250,430
      Shares Outstanding
      84,463,059
      Dividend Yield
      -
      PE Ratio
      -1.99
      Earnings Per Share (EPS)
      -1.61
      Revenue
      -
      Net Profit
      -135.96M

      About Atea Pharmaceuticals Inc

      Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treat... Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Its programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. The company's medicinal chemistry, virology, and pharmacology expertise, bolstered by its collective experience in drug development, enables it to pioneer new advancements in antiviral science. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.ateapharma.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Atea Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker AVIR. The last closing price for Atea Pharmaceuticals was $3.13. Over the last year, Atea Pharmaceuticals shares have traded in a share price range of $ 2.30 to $ 4.60.

      Atea Pharmaceuticals currently has 84,463,059 shares outstanding. The market capitalization of Atea Pharmaceuticals is $264.37 million. Atea Pharmaceuticals has a price to earnings ratio (PE ratio) of -1.99.

      Ask ADVFN Intelligence (AI)

      AVIR Latest News

      More News

      Atea Pharmaceuticals Retains Financial Advisor to Explore Strategic Partnerships

      BOSTON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

      December 16 2024
      GlobeNewswire Inc.

      Atea Pharmaceuticals Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus (HCV)

      Primary Endpoint Achieved with 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) after Short Eight Week Treatment Duration Regimen Was Generally Safe and Well-Tolerated Global...

      December 04 2024
      GlobeNewswire Inc.

      Atea Pharmaceuticals to Present and Provide a Business Update at the 7th Annual Evercore HealthCONx Conference

      BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

      November 26 2024
      GlobeNewswire Inc.

      Form EFFECT - Notice of Effectiveness

      November 20 2024
      Edgar (US Regulatory)

      Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

      BOSTON, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

      November 15 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 07 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 07 2024
      Edgar (US Regulatory)

      Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

      Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of...

      November 07 2024
      GlobeNewswire Inc.

      Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

      BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

      October 31 2024
      GlobeNewswire Inc.

      Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024

      BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

      October 30 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.29102.93.272.8758324443.11366109CS
      4-0.07-2.14723926383.263.542.754457463.10419884CS
      12-0.3-8.595988538683.493.862.752504303.23548323CS
      26-0.27-7.803468208093.464.1452.32438483.43801458CS
      520.13.236245954693.094.62.33049453.67461163CS
      156-5.36-62.69005847958.559.792.35065945.15997655CS
      2602.3675287.8419452890.822594.17370.822583992915.00894585CS

      AVIR - Frequently Asked Questions (FAQ)

      What is the current Atea Pharmaceuticals share price?
      The current share price of Atea Pharmaceuticals is $ 3.19
      How many Atea Pharmaceuticals shares are in issue?
      Atea Pharmaceuticals has 84,463,059 shares in issue
      What is the market cap of Atea Pharmaceuticals?
      The market capitalisation of Atea Pharmaceuticals is USD 264.37M
      What is the 1 year trading range for Atea Pharmaceuticals share price?
      Atea Pharmaceuticals has traded in the range of $ 2.30 to $ 4.60 during the past year
      What is the PE ratio of Atea Pharmaceuticals?
      The price to earnings ratio of Atea Pharmaceuticals is -1.99
      What is the reporting currency for Atea Pharmaceuticals?
      Atea Pharmaceuticals reports financial results in USD
      What is the latest annual profit for Atea Pharmaceuticals?
      The latest annual profit of Atea Pharmaceuticals is USD -135.96M
      What is the registered address of Atea Pharmaceuticals?
      The registered address for Atea Pharmaceuticals is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Atea Pharmaceuticals website address?
      The website address for Atea Pharmaceuticals is www.ateapharma.com
      Which industry sector does Atea Pharmaceuticals operate in?
      Atea Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MYSZMy Size Inc
      $ 4.2001
      (211.12%)
      		121.03M
      NVNINVNI Group Ltd
      $ 8.26
      (209.36%)
      		78.06M
      TPICTPI Composites Inc
      $ 2.45
      (100.82%)
      		34M
      ICGIntchains Group Ltd
      $ 8.77
      (88.60%)
      		527.94k
      HSDTHelius Medical Technologies Inc
      $ 0.884851
      (84.34%)
      		121.95M
      CYNCYNGN Inc
      $ 0.4603
      (-71.41%)
      		27.91M
      MTEMMolecular Templates Inc
      $ 0.1502
      (-57.09%)
      		8.75M
      PRFXPainReform Ltd
      $ 5.15
      (-53.85%)
      		2.94M
      GALTGalectin Therapeutics Inc
      $ 1.03
      (-48.50%)
      		9.27M
      BCABBioAtla Inc
      $ 0.6923
      (-41.82%)
      		6.25M
      EDBLEdible Garden AG Inc
      $ 0.24
      (65.06%)
      		354.32M
      APTOAptose Biosciences Inc
      $ 0.28
      (64.51%)
      		305.1M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.606999
      (6.49%)
      		292.16M
      NVDANVIDIA Corporation
      $ 134.70
      (3.08%)
      		287.21M
      PLTRPalantir Technologies Inc
      $ 80.55
      (8.54%)
      		277.63M

      AVIR Discussion

      View Posts
      DewDiligence DewDiligence 3 months ago
      AVIR phase-3 COVID trial fails—stock rises:

      https://www.globenewswire.com/news-release/2024/09/13/2945844/0/en/Atea-Pharmaceuticals-Provides-Update-on-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Bemnifosbuvir-for-Treatment-of-COVID-19.html Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)…today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. This trial was a longshot insofar as Bemnifosbuvir is a repurposed HCV drug rather than something designed specifically for SARS-CoV-2. Moreover, the phase-2 trial for Bemnifosbuvir in COVID was unsuccessful, but AVIR plowed ahead anyhow.

      I presume the share price is up slightly today because investors know that AVIR won’t waste more money pursuing COVID. AVIR had about $475M of net current assets as of 6/30/24.

      AVIR’s CEO, Jean-Pierre Sommadossi, is continuing to pursue a treatment regimen for HCV, which is a rather extreme case of Zebra’s Law (#msg-172559198).
      👍️0
      Monksdream Monksdream 4 months ago
      AVIR under $4
      👍️0
      DewDiligence DewDiligence 4 months ago
      AVIR reports 2Q24 results—6/30/24 cash=$502.2M—down_from_$542M_at_3/31/24:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500091.html

      CC slides:
      https://ir.ateapharma.com/static-files/96ee237a-23d9-4515-8401-69794a5327e0
      👍️0
      DewDiligence DewDiligence 7 months ago
      AVIR 1Q24 results:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500150.html

      3/31/24 cash = $542M, down from $578M at 12/31/23.

      Final results from the phase-3 SUNRISE COVID trial are expected in 2H24 (no change relative to the prior guidance). There are no interim analyses (#msg-174125019).
      👍️0
      Monksdream Monksdream 8 months ago
      AVIR under $5
      👍️0
      DewDiligence DewDiligence 9 months ago
      AVIR completes enrollment of phase-3 COVID trial—cancels interim analyses:

      https://www.globenewswire.com/news-release/2024/03/27/2853010/0/en/Atea-Pharmaceuticals-Completes-Patient-Enrollment-in-Global-Phase-3-SUNRISE-3-Trial-Evaluating-Oral-Antiviral-Bemnifosbuvir-for-COVID-19-in-High-Risk-Patients.html Atea Pharmaceuticals…today announced that the company has completed enrollment of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, or placebo for the treatment of COVID-19. Over 2,200 patients were randomized into the supportive care monotherapy cohort… The primary endpoint of the trial is all-cause hospitalization or death through Day 29 post-treatment in the bemnifosbuvir supportive care monotherapy cohort of high-risk patients. The two planned interim analyses have been canceled: “Since full enrollment was achieved ahead of the two planned interim analyses for safety and futility by the Data Safety Monitoring Board (DSMB), the analyses are no longer relevant, and in agreement with the DSMB, we will proceed to the full analysis of the trial. We look forward to reporting SUNRISE-3 results in the second half of 2024…
      👍️0
      DewDiligence DewDiligence 10 months ago
      AVIR phase-3 COVID update:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-fourth-quarter-210500983.html

      The first and second interim analyses in the phase-3 COVID trial will be performed in March and in 2Q24, respectively, and the final results will be available in 2H24. 1,400 patients have been enrolled in the bemnifosbuvir monotherapy cohort (the cohort that the primary endpoint is based on).

      AVIR had $578M of cash at 12/31/23, which is why they can afford to blow so much money on a longshot trial.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR rejects Tang buyout offer, as expected:

      https://www.globenewswire.com/news-release/2023/05/30/2678205/0/en/Atea-Pharmaceuticals%5B%E2%80%A6%5DTang-Capital-Partners-Affiliate-Concentra-Biosciences.html

      The offer was for less than AVIR’s cash value.
      👍️0
      DewDiligence DewDiligence 2 years ago
      It's not a serious offering for the reason mentioned in #msg-171974875.
      👍️0
      mwn mwn 2 years ago
      Why is the sp going so far below the offering?
      👍️0
      DewDiligence DewDiligence 2 years ago
      Yes.
      👍️0
      Paullee Paullee 2 years ago
      Did you not notice that a CVR of 80% is included in the package?
      👍️0
      DewDiligence DewDiligence 2 years ago
      In other words, AVIR could do better than $5.75/sh by simply liquidating.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR acknowledges Tang buyout offer—makes_no_recommendation_to_shareholders—(yet):

      https://www.globenewswire.com/news-release/2023/05/23/2674788/0/en/Atea-Pharmaceuticals-Confirms-Receipt-of-Unsolicited-Proposal-from-Tang-Capital-Partners-Affiliate-Concentra-Biosciences.html

      Even thought Tang’s $5.75/sh offer is a big premium to where AVIR was trading prior to the offer, it’s less than AVIR’s cash value per share. Hence, it’s hard to see how AVIR’s BoD could accept the offer. They could make a counter-proposal, of course.
      👍️0
      DewDiligence DewDiligence 2 years ago
      Tang Capital makes_unsolicited AVIR buyout offer@$5.75/sh +CVR—a_55%_premium_to_Friday’s_close:

      https://www.sec.gov/Archives/edgar/data/1593899/000121465923007616/z519230sc13d.htm (scan to bottom)

      Why does Tang want to acquire AVIR? Presumably for AVIR’s COVID drug, AT-527, such as it is. AT-527 is a polymerase inhibitor that is similar to an HCV drug BMY dropped several years ago due to toxicity. AVIR is conducting a phase-3 trial in high-risk COVID patients using a daily dose of 1100 mg (550mg BID); the trial listing is at: https://www.clinicaltrials.gov/ct2/show/NCT05629962 .
      👍️0
      Awl416 Awl416 2 years ago
      Volume
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 1Q23 CC transcript:

      https://finance.yahoo.com/news/q1-2023-atea-pharmaceuticals-inc-140930636.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 1Q23 results:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-200500951.html

      3/31/23 cash = $621M.
      👍️0
      V63 V63 2 years ago
      So AVIR beat its earnings, and now it might bump up a little tomorrow.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR reports final data from phase-2 COVID trial:

      https://www.globenewswire.com/news-release/2023/04/12/2645185/0/en/Atea-Announces-Presentation-of-Bemnifosbuvir-Data-Demonstrating-Reduced-Hospitalizations-for-COVID-19-Patients-at-2023-European-Congress-of-Clinical-Microbiology-Infectious-Disease.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 4Q22 CC transcript:

      https://finance.yahoo.com/news/atea-pharmaceuticals-inc-nasdaq-avir-022000995.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 4Q22 results—12/31/22 cash=$647M:

      https://www.globenewswire.com/news-release/2023/02/28/2617674/0/en/Atea-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

      AVIR expects the interim analysis of the SUNRISE-3 (COVID) phase-3 trial to occur in 2H23. One possible outcome of the interim analysis is increasing the number of patients to provide more statistical power for the final analysis.
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR JPM webcast slides:

      https://ir.ateapharma.com/static-files/731c461d-37e4-4364-8a12-eb605580b0aa
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 2023 newsflow:

      https://finance.yahoo.com/news/atea-pharmaceuticals-highlights-strategic-priorities-120000077.html
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 3Q22 results—9/30/22 cash=$665M:

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-third-quarter-210500282.html

      A phase-3 trial of Bemnifosbuvir (f/k/a AT-527) in 1,500 high-risk, non-hospitalized COVID patients is expected to start by the end of 2022. AVIR is defining “high-risk” as: a) age 80+; b) age 65+ with 1 or more major risk factors; or c) an immunocompromised adult of any age.

      The daily dose of Bemnifosbuvir is a whopping 1100mg (550mg BID).
      👍️0
      DewDiligence DewDiligence 2 years ago
      AVIR 2Q22 results—6/30/22_cash=$684.5M (down from $705.5M at 3/31/22):

      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-second-quarter-200500782.html
      👍️0
      DewDiligence DewDiligence 3 years ago
      AVIR 3/31/22 cash=$705.5M—burning $58.9M in 1Q22...

      1Q22 PR:
      https://finance.yahoo.com/news/atea-pharmaceuticals-reports-first-quarter-103000747.html

      1Q22 CC slides:
      https://ir.ateapharma.com/static-files/8a966559-367b-4a3b-96c0-ff21958c0562
      👍️0
      DewDiligence DewDiligence 3 years ago
      LOL re AVIR’s attempt to be relevant:

      https://www.globenewswire.com/news-release/2021/12/14/2352116/0/en/Atea-Pharmaceuticals-Introduces-New-Strategic-Clinical-Development-Program-for-AT-527-in-COVID-19.html
      👍️0
      Jake L Jake L 3 years ago
      AVIR - Friday Rundown, Monday Expectations

      👍️0
      Wallst_junkie Wallst_junkie 3 years ago
      Watching for a uptrend
      👍️0
      dealerschool2006 dealerschool2006 3 years ago
      GOOD JOB!!! ya, by the time I discovered AVIR it had gone up 50% from the bottom...
      👍️0
      crudeoil24 crudeoil24 3 years ago
      Wow! That's why you don't hold these Pharma overnight.

      AVIR
      👍️0
      TheFinalCD TheFinalCD 3 years ago
      wow went sub $11 and traded the whole float, shit it traded the whole OS 1.5x today https://finviz.com/quote.ashx?t=AVIR
      👍️0
      DewDiligence DewDiligence 3 years ago
      Why AVIR's AT-527 program is no-go: #msg-166425975.
      👍️0
      XWAVXALMIMAN XWAVXALMIMAN 3 years ago
      David v Goliath

      Interesting article - check out RDHL

      https://www.yahoo.com/entertainment/david-v-goliath-race-develop-123328764.html
      👍️0
      Chess Master Chess Master 3 years ago
      What a drop
      👍️0
      ecommceo ecommceo 3 years ago
      Way over sold here.
      👍️0
      Planopenny Planopenny 3 years ago
      Out at $16, easy $$$
      👍️0
      Docstemcell2020 Docstemcell2020 3 years ago
      Let's go Brandon! FJB :)
      👍️0
      DewDiligence DewDiligence 3 years ago
      AVIR CC slides (largely BS, IMO):

      https://ir.ateapharma.com/static-files/d72bd065-82b3-4eeb-ad3a-40c5518d66d6
      👍️0
      Planopenny Planopenny 3 years ago
      In at $10
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      Well the shit just hit the fan. Didn’t meet primary in study. Stock dow $28
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      Thanks DD
      👍️0
      DewDiligence DewDiligence 3 years ago
      The primary endpoint in MRK’s molnupiravir trial was the proportion of patients, relative to placebo, who died or needed hospitalization within 28 days:

      https://clinicaltrials.gov/ct2/show/NCT04575597
      👍️0
      rosemountbomber rosemountbomber 3 years ago
      So I have to confess to my ignorance when it comes to anti-viral clinical trials. It appears that the primary outcome studied in the AT-527 phase 3 trial is evaluated using a Covid 19 Symptom Diary. It does not sound like it is something very precise when asking a patient to score themselves on these 12 questions (which I have not exactly found yet).

      But my question is, did the Merck drug molnupiravir get tested using this same method (symptom diary)? It must have been more than that at least as they also measure deaths, etc. - although that may have been secondary outcomes.
      👍️0
      Whalatane Whalatane 3 years ago
      AVIR presentation tomorrow Oct 5th

      https://newsfilter.io/articles/atea-pharmaceuticals-to-present-at-guggenheim-2nd-annual-vaccines--infectious-day-conference-42a958b2016103f267b2f6525ac4ac0c

      Kiwi
      👍️0
      crudeoil24 crudeoil24 3 years ago
      You bet! > AVIR up 45% @ 50.05
      👍️0
      Whalatane Whalatane 3 years ago
      Thx for the updates

      Kiwi
      👍️0
      crudeoil24 crudeoil24 3 years ago
      AVIR up 45% @ 50.05 > premarket.
      👍️0
      crudeoil24 crudeoil24 3 years ago
      AVIR > 53M share trading float.
      👍️0

      Your Recent History

      NASDAQ
      AVIR
      Atea Pharmaceuticals
      BIT
      JCHE
      JPMorgan BetaBuilders Ch...
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads